Nidan Laboratories Key Ratios
NSE: NIDAN
₹13.50
₹0.35
(2.66%)
As on 11-Sep-2026IST
Market cap
₹19 Cr
Revenue (TTM)
₹25 Cr
P/E Ratio
12.5
P/B Ratio
0.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 1.45 | -6.14 | 2.76 |
| EBIT | -- | -- | -25.85 | -26.86 | -9.82 |
| Net Profit | -- | -- | 161.16 | -9.45 | 22.57 |
| EPS | -- | -- | 161.16 | -9.45 | -- |
| Book Value | -- | -- | 2.99 | 1.14 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| 13.63 | 18.35 | 10.82 | 14.80 | 15.27 |
| Net Margin
| 2.73 | 5.56 | 7.38 | -12.01 | 12.83 |
| Return on equity
| 1.14 | 5.81 | 2.94 | -4.77 | 5.23 |
| Return on Capital
| 4.82 | 7.80 | 6.21 | -0.24 | 8.50 |
| Return on Assets
| 0.88 | 2.21 | 2.41 | -3.90 | 4.12 |
| Debt to Equity (x)
| -- | -- | 0.16 | 0.19 | 0.16 |
Profitability
ROCE
6.21
Lower than Peers by 14.04
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
6.21
|
-0.24
|
8.50
|
10.52
|
13.98
|
|
Peer Median
|
20.26
|
19.83
|
33.53
|
37.00
|
--
|
ROE
2.94
Lower than Peers by 10.99
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
2.94
|
-4.77
|
5.23
|
6.72
|
18.90
|
|
Peer Median
|
13.93
|
15.80
|
26.65
|
26.85
|
--
|
ROA
2.41
Lower than Peers by 7.59
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
2.41
|
-3.90
|
4.12
|
3.76
|
4.68
|
|
Peer Median
|
10.00
|
8.30
|
16.54
|
17.58
|
--
|
EBIT Margin
10.82
Lower than Peers by 8.84
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
10.82
|
14.80
|
15.27
|
22.87
|
27.98
|
|
Peer Median
|
19.66
|
18.70
|
19.68
|
25.18
|
--
|
Net Margin
7.38
Lower than Peers by 4.57
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
7.38
|
-12.01
|
12.83
|
8.86
|
10.74
|
|
Peer Median
|
11.96
|
12.26
|
16.78
|
18.16
|
--
|
Cash Profit Margin
17.88
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
17.88
|
-1.52
|
27.35
|
17.85
|
26.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
1.45
Lower than Peers by 14.29
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
1.45
|
-0.36
|
-18.19
|
45.55
|
-4.81
|
|
Peer Median
|
15.74
|
13.67
|
4.18
|
49.99
|
--
|
EBIT Growth
-25.85
Lower than Peers by 48.45
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
-25.85
|
-3.43
|
-45.37
|
18.95
|
28.21
|
|
Peer Median
|
22.60
|
11.16
|
-14.65
|
108.09
|
--
|
Net Profit Growth
161.16
Higher than Peers by 137.87
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
161.16
|
-191.32
|
32.92
|
15.65
|
222.21
|
|
Peer Median
|
23.29
|
9.39
|
-16.12
|
151.45
|
--
|
EPS Growth
161.16
Higher than Peers by 131.73
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
161.16
|
-191.32
|
32.92
|
-17.63
|
222.21
|
|
Peer Median
|
29.43
|
-7.32
|
-35.05
|
150.72
|
--
|
Book Value Growth
2.99
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
2.99
|
-4.66
|
5.37
|
394.33
|
20.88
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.16
Higher than Peers by 0.12
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
0.16
|
0.19
|
0.16
|
0.29
|
2.85
|
|
Peer Median
|
0.05
|
0.08
|
0.15
|
0.03
|
--
|
Short term debt to equity ratio
0.10
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
0.10
|
0.11
|
0.07
|
0.13
|
0.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.10
Lower than Peers by 1.32
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
1.10
|
2.67
|
2.18
|
1.98
|
0.88
|
|
Peer Median
|
2.42
|
2.28
|
1.88
|
2.40
|
--
|
Quick Ratio
1.05
Lower than Peers by 1.32
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
1.05
|
2.65
|
2.14
|
1.96
|
0.87
|
|
Peer Median
|
2.37
|
2.33
|
1.78
|
3.09
|
--
|
Interest Coverage
2.29
Lower than Peers by 5.33
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
2.29
|
-0.09
|
3.16
|
2.70
|
1.95
|
|
Peer Median
|
7.61
|
10.16
|
11.52
|
12.12
|
--
|
Operating Efficiency
Debtors to sales
5.17
Lower than Peers by 5.45
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
5.17
|
2.17
|
24.83
|
18.08
|
26.66
|
|
Peer Median
|
10.62
|
7.60
|
14.45
|
9.16
|
--
|
Asset Turnover
0.30
Lower than Peers by 0.51
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
0.30
|
0.29
|
0.28
|
0.42
|
0.41
|
|
Peer Median
|
0.81
|
0.77
|
0.86
|
1.18
|
--
|
Receivable days
13.34
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
13.34
|
49.45
|
85.65
|
66.41
|
97.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
6.32
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
6.32
|
5.04
|
4.37
|
1.98
|
1.72
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
397.84
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
397.84
|
168.52
|
227.04
|
144.01
|
91.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
-378.19
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
-378.19
|
-114.04
|
-137.03
|
-75.62
|
7.61
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
11.64
Lower than Peers by 47.84
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
11.64
|
--
|
13.29
|
17.33
|
--
|
|
Peer Median
|
59.48
|
60.28
|
46.86
|
69.67
|
--
|
Price / Book Value
0.34
Lower than Peers by 9.30
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
0.34
|
0.57
|
0.68
|
0.70
|
--
|
|
Peer Median
|
9.63
|
8.84
|
6.59
|
10.70
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.04
|
0.42
|
0.38
|
0.06
|
--
|
EV/EBITDA
4.41
Lower than Peers by 43.76
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
4.41
|
5.13
|
4.89
|
5.84
|
4.09
|
|
Peer Median
|
48.17
|
47.88
|
27.71
|
45.91
|
--
|
Market Cap
23
Lower than Peers by 8,599
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Nidan Laboratories
|
23
|
38
|
47
|
46
|
--
|
|
Peer Median
|
8,622
|
9,694
|
5,629
|
5,992
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
